1 BTC
=
- USD
Bausch + Lomb Corporation
As of May 30, 2026 at 24:05 UTC
Chart
About Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Market Statistics
Trading Metrics
How to Buy BLCO
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy BLCO
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesBausch + Lomb director Alfonso Eduardo purchased 4,300 shares for approximately $77,000 on March 2, 2026, at $17.90 per share. The company matched his purchase with 4,300 restricted stock units granted at no cost, vesting over three years. As a new director (joined January 1, 2026), Eduardo is working toward a mandatory $400,000 equity ownership requirement within five years, with this transaction bringing him to roughly $248,000 of that threshold.
The Portnoy Law Firm has initiated a securities fraud investigation into Bausch + Lomb Corporation following significant stock price declines. The company's stock fell 9.8% on March 28, 2025, after disclosing increased reports of toxic anterior segment syndrome (TASS) related to enVista intraocular lenses, prompting a voluntary recall. A second decline of 15.7% occurred on April 30, 2025, following Q1 2025 results estimating $55 million in revenue and $65 million in adjusted EBITDA headwinds from the recall.
Bausch + Lomb reported $5.1 billion in annual revenue with 6% year-over-year growth, driven by contact lenses, consumer eye health products, and new pharmaceutical launches like MIEBO. Caspian Capital increased its stake by 1.35 million shares to $34.14 million, making it the firm's top holding at 22.6% of AUM. Despite underperforming the S&P 500 over the past year, the stock has stabilized recently and analysts view the investor's conviction as a positive signal.
The global ophthalmic drugs market is projected to reach US$41.88 billion in 2026 and grow at 7.9% CAGR through 2036, driven by biologic innovation, anti-VEGF therapies, AI-enabled diagnostics, and long-acting drug delivery systems. Key developments include expanded digital distribution channels and sustained-release implants reducing treatment burden for retinal disorders.
Nicox announced positive Phase 3 data for NCX 470, a nitric oxide-donating bimatoprost eye drop, presented at the American Glaucoma Society 2026 congress. The drug demonstrated intraocular pressure (IOP) reduction up to 10 mmHg, meeting efficacy requirements for U.S. and China regulatory approvals. NCX 470 showed superior IOP reduction compared to latanoprost at three of six measurement points and demonstrated a favorable safety profile with low treatment discontinuation rates.